We are live on ! Find out more
PSTX

Poseida Therapeutics, Inc. Common Stock
PSTX

Delisted

PSTX was delisted on the 7th of January, 2025.

Back to rankings

64 hedge funds and large institutions have $107M invested in Poseida Therapeutics, Inc. Common Stock in 2022 Q1 according to their latest regulatory filings, with 12 funds opening new positions, 16 increasing their positions, 21 reducing their positions, and 14 closing their positions.

New
Increased
Maintained
Reduced
Closed

3% less funds holding

Funds holding: 66 → 64 (-2)

14% less first-time investments, than exits

New positions opened: 12 | Existing positions closed: 14

24% less repeat investments, than reductions

Existing positions increased: 16 | Existing positions reduced: 21

40% less capital invested

Capital invested by funds: $178M → $107M (-$71.1M)

Holders
64
Holders Change
-2
Holders Change %
-3.03%
% of All Funds
1.01%
Holding in Top 10
1
Holding in Top 10 Change
+1
Holding in Top 10 Change %
% of All Funds
0.02%
New
12
Increased
16
Reduced
21
Closed
14
Calls
$54K
Puts
–
Net Calls
+$54K
Net Calls Change
+$43K

Top Buyers

Rank Fund Capital Flow
1
Renaissance Technologies
Renaissance Technologies
New York
+$692K
2
CC
Corton Capital
Ontario, Canada
+$262K
3
MA
MCF Advisors
Kentucky
+$259K
4
Dimensional Fund Advisors
Dimensional Fund Advisors
Texas
+$213K
5
DU
Delphia (USA)
Ontario, Canada
+$184K

Top Sellers

Rank Fund Capital Flow
1
N
Natixis
France
-$11.6M
2
Jacobs Levy Equity Management
Jacobs Levy Equity Management
New Jersey
-$1.42M
3
PVI
Pura Vida Investments
New York
-$612K
4
GCP
GSA Capital Partners
United Kingdom
-$577K
5
BlackRock
BlackRock
New York
-$379K
Name Holding Trade Value Shares
Change 		Change in
Stake
Citigroup
51
Citigroup
New York
$17K -$23.9K -5,303 -59%
AB
52
Amalgamated Bank
New York
$16K +$15.6K +3,462 New
AF
53
Amalgamated Financial
New York
$16K +$15.6K +3,462 New
Royal Bank of Canada
54
Royal Bank of Canada
Ontario, Canada
$13K -$13.6K -3,007 -50%
TRCT
55
Tower Research Capital (TRC)
New York
$13K +$6.43K +1,426 +90%
AIP
56
Ameritas Investment Partners
Nebraska
$12K – – –
Legal & General Group
57
Legal & General Group
United Kingdom
$10K – – –
PFBT
58
Parkside Financial Bank & Trust
Missouri
$9K +$9.02K +2,000 New
TWC
59
TD Waterhouse Canada
Ontario, Canada
$7.11K – – –
Rockefeller Capital Management
60
Rockefeller Capital Management
New York
$5K – – –
SCM
61
Silverarc Capital Management
Massachusetts
$1.07K +$21.5K +4,764 +2%
Daiwa Securities Group
62
Daiwa Securities Group
Japan
$1K – – –
N
63
Natixis
France
– -$11.6M -1,700,000 Closed
PVI
64
Pura Vida Investments
New York
– -$612K -89,886 Closed
GCP
65
GSA Capital Partners
United Kingdom
– -$577K -84,701 Closed
PFMU
66
Privium Fund Management (UK)
United Kingdom
– -$350K -48,470 Closed
CSS
67
Cubist Systematic Strategies
Connecticut
– -$160K -23,432 Closed
Ohio Public Employees Retirement System (OPERS)
68
Ohio Public Employees Retirement System (OPERS)
Ohio
– -$156K -22,903 Closed
DMKJ
69
David M. Knott Jr
– -$133K -19,566 Closed
Susquehanna International Group
70
Susquehanna International Group
Pennsylvania
– -$115K -16,863 Closed
UBS Group
71
UBS Group
Switzerland
– -$67K -9,795 Closed
HNWAG
72
High Net Worth Advisory Group
Florida
– -$1K -200 Closed
PA
73
Parallel Advisors
California
– -$1K -105 Closed
LC
74
Lindbrook Capital
California
– -$1K -101 Closed
EWM
75
Edge Wealth Management
New York
– -$1K -50 Closed
1 2
3
4

PSTX Hedge Fund Activity: Q1 2022 in Review

64 of the 6,341 institutional investors tracked by Wall St. Rank reported a position in Poseida Therapeutics, Inc. Common Stock (PSTX) for Q1 2022, worth a combined $107M — down 40% from $178M a quarter earlier.

Sellers outnumbered buyers: 14 funds closed out of PSTX and 12 opened new positions — a net loss of 2 holders — while 21 trimmed existing stakes and 16 added.

The largest buyer was Renaissance Technologies, adding an estimated $692K. The largest seller was Natixis, exiting entirely with an estimated $11.6M sold.

  • 64 institutional investors held Poseida Therapeutics, Inc. Common Stock (PSTX) as of Q1 2022, down from 66 in Q4 2021.
  • Funds reported $107M of Poseida Therapeutics, Inc. Common Stock stock for Q1 2022, down 40% quarter-over-quarter.
  • 12 funds opened new Poseida Therapeutics, Inc. Common Stock positions in Q1 2022 and 14 closed out, a net change of -2 holders.
  • The largest Poseida Therapeutics, Inc. Common Stock buyer in Q1 2022 was Renaissance Technologies, an estimated $692K added.
  • The largest Poseida Therapeutics, Inc. Common Stock seller in Q1 2022 was Natixis, an estimated $11.6M sold.

Based on aggregated 13F filings for Q1 2022.